Eli Lilly is doubling down on its partnership with Chinese tech outfit XtalPi, striking a new antibody development pact that could net a subsidiary of the artificial intelligence drug discovery shop as much as $345 million.
<a href="https://www.fiercebiotech.com/biotech/lilly-expands-xtalpi-collaboration-345m-antibody-development-pact" hreflang="en">Lilly inks $345M antibody development pact with XtalPi subsidiary</a>
FierceBiotech | | Darren Incorvaia
Topics: research